Unlock instant, AI-driven research and patent intelligence for your innovation.

A pharmaceutical composition useful for treating chronic myeloid leukemia

A composition and leukemia technology, which can be used in drug combinations, anti-tumor drugs, pharmaceutical formulations, etc., and can solve problems such as weak prognosis in CML

Inactive Publication Date: 2005-10-05
COUNCIL OF SCI & IND RES
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Despite tremendous advances in clinical medicine, the prognosis of CML remains weak (1)

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A pharmaceutical composition useful for treating chronic myeloid leukemia
  • A pharmaceutical composition useful for treating chronic myeloid leukemia
  • A pharmaceutical composition useful for treating chronic myeloid leukemia

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0030] Accordingly, the present invention provides a pharmaceutical composition useful for the treatment of chronic myeloid leukemia in which Bcr-Abl kinase is constitutively expressed in animals and humans, said composition containing an effective amount of chlorogenic acid like substances and / or their salts and pharmaceutically acceptable additives.

[0031] In one embodiment of the invention, the composition is also useful in the treatment of diseases caused by overexpression of Abl-type kinases.

[0032] In another embodiment, the analogue of chlorogenic acid is selected from neochlorogenic acid (5-O-caffeoylquinic acid), cryptochlorogenic acid (cryptochlorogenic acid) (4-O-caffeoylquinic acid) Nicotinic acid), 3-O-(3'-methylcaffeoyl)quinic acid and 5-O-(caffeoyl-4'-methyl)quinic acid.

[0033] In yet another embodiment, the chlorogenic acid analogs are obtained from natural sources or made synthetically.

[0034] In yet another embodiment, the salt of the chlorogenic ac...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to a pharmaceutical composition useful for treating chronic myeloid leukemia where Bcr-Abl kinase is constitutively expressed in animals and humans, said composition comprising an effective amount of analogs of chlorogenic acid such as neochlorogenic acid (5-O- caffeoyl quinic acid), cryptochlorogenic acid (4-O-Caffeoyl quinic acid), 3- O- (3'-methylcaffeoyl) quinic acid and 5-O-(Caffeoyl-4'-methyl) quinic acid and / or its salts such as sodium, potassium and ammonium together with pharmaceutically acceptable additives.

Description

technical field [0001] The present invention relates to the treatment of chronic myeloid leukemia (CML) by means of compositions containing chlorogenic acid analogs and / or salts thereof, for example sodium or potassium or ammonium chlorogenic acid prepared from chlorogenic acid or analogs thereof Treatment. [0002] Chronic myeloid leukemia is lethal, there are no drugs directed at destroying the leukemia cells, and these cells respond poorly to chemotherapy, which is always nonspecific and thus adversely affects normal cells. This therapy with NaChl is unique in that it kills the bone marrow cancer cells while leaving normal cells unaffected. Background technique [0003] Myeloid leukemia is generally divided into two groups: acute myeloid leukemia (AML) and chronic myeloid leukemia (CML). AML is characterized by an increase in the number and arrest of myeloid cell maturation in the bone marrow. In the United States, the annual incidence of AML is approximately 2.4 per 1...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/215A61P35/02
Inventor S·班德约帕德亚B·C·帕尔S·巴塔查尔亚K·C·洛伊G·班德约帕德亚
Owner COUNCIL OF SCI & IND RES